Obesity

A low-carbohydrate diet that emphasized high-quality protein, fat and carbohydrates from healthful plant-based sources was linked to less weight gain over a 4-year period, according to a recent study.

A high BMI in late adolescence — even a high-normal BMI — was associated with increased odds of early chronic kidney disease in young adulthood, according to a study published in JAMA Pediatrics.

Patients with type 2 diabetes and chronic kidney disease receiving empagliflozin were less likely to experience a decline in eGFR compared with patients taking placebo, results from a newly published study show.

Eli Lilly and Co. released an open letter stating its tirzepatide products should not be used for cosmetic weight loss and warning the public about the circulation of compounded and counterfeit tirzepatide.

About two-thirds of adults who were prescribed an obesity medication stop taking them after 6 months, and 80% discontinued use at 1 year, according to a retrospective cohort study.

Despite years of progress, severe obesity among children from households with lower incomes is just as prevalent as it was a decade ago and trending upward, according to a study published in Pediatrics.

Healio | Cardiology Today compiled a list of some of the most important news in cardiology from 2023.

Adults who initiated once-weekly semaglutide after not responding to bariatric surgery lost a similar amount of weight as those without a history of bariatric surgery, according to study findings published in Obesity.

The SELECT trial, which showed semaglutide, a GLP-1 receptor agonist also approved for diabetes, reduced CV events in people with overweight/obesity and CVD but no diabetes, was one of the most important developments in cardiology in 2023.

According to a recent study, more than half of the United States population eligible for semaglutide could lose at least 15% of their body weight after treatment with the medication.